One of the companies that could well be worth keeping an eye on over the upcoming days could be HippoFi (OTC:ORHB), especially in light of the latest announcement. PUR Biologics, the company’s biotech business, came into focus yesterday after it announced that it had appointed a new Head of Sales in the form of Scott Bauccio. Such a major appointment may be of considerable interest to investors, and hence, it could be a good idea to take a closer look into his credentials.
In the news release, the company announced that Bauccio boasted two decades worth of sales management and also commanded a major sales network that was the envy of the industry. He had been tasked with the expansion of the sales and distribution channels at PUR Biologics. He had already been successful in coming up with two products. One of those is PURamnio, which has already gone on sale, and the other is PURpeptide, which will imminently go on sale.
The head of PUR Biologics, Ryan Fernan, spoke about the latest appointment as well. He noted that everyone at the company was excited about the possibility of Bauccio joining the team. Fernan also stated that Bauccio also had a proven track record of success and had also demonstrated a strong ability to set up a strong market presence. All those attributes were perfectly aligned with the objectives of PUR Biologics.
The Chief Executive Officer and Executive Chairman of HippoFi, CJ Wiggins, expressed their thoughts about the appointment. He stated that the appointment was a tactical move aimed at boosting the leadership team of the company at a key juncture in the growth journey. He went on to state that the market insight and industry-level expertise were going to be invaluable in HippoFi’s constant pursuit of innovation.